SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: A.J. Mullen who wrote (3175)12/7/2020 9:29:57 PM
From: Biotechwantabe  Respond to of 3557
 
Important to look at the full oncology & hematology program. Great to see a big investment. Long term will be more important than infectious disease program.



To: A.J. Mullen who wrote (3175)12/8/2020 1:02:43 PM
From: Miljenko Zuanic  Read Replies (1) | Respond to of 3557
 
Yes, BCMA and MM is way to crowded market, so small difference will benefit some. The totality of the cancer programs (hematology and solid) is what will draw long term prospect. REGN is "continuously* talking about, but we need to see FIRST HAND EVIDENCE, that are not there so far!!??


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News